The study of plasma biomarker for early diagnosis of Alzheimer disease / 中华老年医学杂志

ABSTRACT

Objective To extract,detect and validate the BACE1 expression-regulating lncRNA BACE1-AS containing in the plasma of patients with AD in Chinese Han people,so as to provide a research basis for plasma BACE1-AS in AD to be a plasma molecular markers and a new target for treatment.Methods The study included 27 AD patients and 28 normal individuals whose age,sex,education,etc.were matched between AD and controi group.Total RNA extraction of plasma was performed using guanidine isothiocyanate-phenol chloroform method.Target gene amplification was executed by RT-PCR Kit.Gel electrophoresis and its imaging analysis were performed on the RT-PCR amplified products.Target gene amplified products were sequenced,its sequence consistency with gene bank-reported sequence were compared,and differences in target gene transcription between the two groups were statistically analyzed.Results The positive expression rates of BACE1-AS were 18.5％(5/27 cases)in ADgroup and 0.0％ in control group,respectively(P=0.023).In comparison between two groups,there was a significant difference (P =0.023).Gene sequencing confirmed the consistent between BACE1-AS gene sequence of 3 patients with AD and Gene Bank's BACE1-AS sequence.But the two other AD cases showed individual base replacement.Conclusions Compared with the healthy control group,patients with AD show specific BACE1 expression-regulating lncRNA BACE1-AS in plasma of AD patients,which provides theoretical basis for BACE1 AS as a biomarker of AD diagnosis and a new target in therapy of AD.